Full length articleStrontium substitution in apatitic CaP cements effectively attenuates osteoclastic resorption but does not inhibit osteoclastogenesis
Graphical abstract
Introduction
While autologous bone transplantation is still regarded as gold-standard in bone defect regeneration that requires defect filling, a variety of bone substitute materials have been developed and investigated in the last decades, including metals, polymers, ceramics and glasses/glass ceramics [1], [2], [3]. For defects of small, however critical size defects in non-load bearing locations calcium phosphate bone cements (CPC) have become a widely used bone substitute material [4], [5]. This is without doubt justified by their excellent biocompatibility and osteoconductivity, as well as their resorbability that allows implant degradation upon the formation of new bone tissue in vivo [5]. Degradation of CPC by means of physico-chemical dissolution has been subject of many studies and a variety of solutions and experimental setups have been used as discussed recently by Ito et al. [6]. In contrast to brushite-forming cements that possess a high solubility, apatite forming cements are known to exhibit very low degradation rates in neutral, aqueous solutions [5]. However, under in vivo conditions cell-mediated resorption by osteoclasts, often referred to as biodegradation, adds up to the physico-chemical degradation, allowing the remodeling of the material into bone tissue [5], [7]. Osteoclasts (OC) are multi-nucleated cells originating from monocyte lineage that can resorb mineralized tissues. Proliferation and differentiation of these precursors into mature, resorbing OC is regulated via two distinct cytokines, the macrophage colony-stimulating growth factor (M-CSF) and the receptor activator nuclear factor κB ligand (RANKL) [8]. After attaching to the substrate, OC form a tight bond to the substrate surface, creating a sealing zone between the cell and the material where resorption takes place. Inorganic calcium phosphate is dissolved by acidification of the resorption zone while organic components are degraded enzymatically [8], [9].
Strontium ions (Sr2+) have been used in osteoporosis therapy in the form of strontium ranelate because they exhibit a stimulating effect on new bone formation by osteoblasts [10], [11], [12]. However, the mechanism how strontium also affects osteoclasts, or rather their resorption activity, is still not yet fully understood. In a study using chicken bone marrow derived OC like cells, Baron et al. demonstrated an inhibitory effect of strontium on the expression of carbonic anhydrase II (CAII), a key enzyme for bone resorption, that allows the degradation of bone mineral via the acidification of the resorption area [13]. In the same study, strontium was also shown to affect the formation of the OC ruffled boarder via inhibition of vitronectin receptor (integrin aνβ3) expression, both resulting in a decrease of resorption activity. Interestingly, neither osteoclastogenesis nor cell attachment to the substrate surface was affected by the presence of strontium [13], [14]. A possible target for Sr2+ affecting OC is the calcium sensing receptor (CaSR) which can be found in most osteoclasts and that is known to interact also with other divalent ions. In cultures of primary mature rabbit OC, activation of the CaSR by strontium ions stimulates apoptosis in a dose-dependent manner. Interestingly, the same study suggests that this effect derives from a potentiating effect of strontium on the induction of mature OC apoptosis by calcium through parallel and converging pathways [15]. The CaSR was also shown to reduce RANKL-induced osteoclastogenesis in murine cell lines as well as in cultures of human peripheral blood monocytes (PBMC) [16]. Another mechanism how strontium affects OC was proposed by Bakker et al., who demonstrated that Sr2+ can affect the paracrine signaling of osteocytes towards OC [17]. Albeit a number of approaches towards the integration of strontium ions into CPC have been described [18], to the best knowledge of the authors no data on in vitro osteoclastogenesis and substrate resorption under the influence of SrCPC have been published yet. Only one study by Yang et al. demonstrated that osteoclastic activity, by means of resorption pit area, decreased significantly with increasing strontium content of mineralized films prepared by precipitation from calcium and strontium containing liquids, a material resembling a set SrCPC [19]. An α-TCP-based cement system (CPC) comprising anhydrous calcium monohydrogen phosphate (Monetite, CaHPO4), calcium carbonate (CaCO3) and hydroxyapatite (Ca5(PO4)3(OH)) served as control and was used as starting material for strontium-modified cements. SrCPC were obtained by partial or complete substitution of CaCO3 by SrCO3 in the cement precursor (S50 and S100, respectively). This cement system has been extensively studied by us regarding its material characteristics, effect on osteogenic cells in vitro and in vivo bone formation. Besides its improved mechanical characteristics [20], in particular an increased compressive strength, the in vitro study using primary human mesenchymal stem cells revealed an enhanced cell proliferation and a stimulating effect of both S50 and S100 on the osteogenic differentiation that could be attributed to Sr2+ released from the cements and altered calcium absorption behavior [21]. Furthermore, an increased new bone formation was shown 6 weeks post-implantation of S100 in critical size metaphyseal defects in an osteoporotic rat model [22]. Aim of the present work was to study the effect of these SrCPC on osteoclastogenesis and osteoclast-mediated material resorption in vitro to further understand the complex effects of SrCPC on the bone remodeling process comprising both osteogenesis and osteoclastogenesis. In a first approach, strontium chloride (SrCl2) in concentrations resembling those released from the SrCPC was added to the culture medium of PBMC which were stimulated to form functional osteoclasts with M-CSF and RANKL. In a second set of experiments, cells were directly cultivated on two SrCPC and one Sr-free CPC serving as a control. Light and confocal laser scanning microscopy, gene expression analysis of osteoclast-related markers, quantification of osteoclast-specific enzyme activities as well as a SEM-based resorption assay were used to quantify both osteoclastogenesis and resorption activity. The results were correlated to intracellular calcium and strontium level measurements performed by ToF-SIMS.
Section snippets
Cement preparation
SrCPC was obtained by substitution of CaCO3 by SrCO3 in an α-TCP-based cement precursor as described previously [20] and was provided by InnoTERE GmbH. Cements denoted as S50 and S100 contained 1.10 and 2.21 at% strontium, respectively, and Sr-free cement (CPC) was used as control. A cement paste was prepared from the cement powder by mixing with 4 wt.% disodium hydrogen phosphate (Na2HPO4, Sigma-Aldrich) at a liquid-to-powder ratio of 400 μl/g. Cement disks designed to fit into standard 48-well
Effect of Sr2+ on osteoclastogenesis
In a first set of experiments the effects of different SrCl2 concentrations on osteoclastogenesis from PBMC cultured on TCPS was studied. Cell fusion into multinucleated cells could be observed from day 5 on in control samples and at lower SrCl2-concentrations. Histologic staining at day 9 revealed the presence of multinucleated, TRAP-positive cells after 9 days in control and SrCl2-treated samples (Fig. 1). No osteoclast-like cells were found at a SrCl2 concentration of 5 mM and above. At 1 mM
Discussion
Strontium ions have been shown to exert a dual effect on bone metabolism; on the one hand pre-osteoblast proliferation and osteogenic differentiation are stimulated and new bone formation is increased in the presence of Sr2+ ions and on the other hand cell-driven bone resorption by osteoclasts is inhibited [30]. Today, the exact mechanism through which strontium acts on bone cells has not been fully clarified, however, several pathways have been suggested. Strontium has been proposed to act on
Conclusions
In this study we investigated the effects of strontium-substituted calcium phosphate bone cements on the development and resorption activity of osteoclast-like cells from monocyte precursors in vitro. Based on our results the following conclusions can be drawn: (1) Sr2+ concentrations comparable to those released from the substituted cements under in vitro conditions reduce the activity of osteoclast-related enzymes TRAP and CAII, alter the actin cytoskeleton organization (0.1 mM) but do not
Acknowledgements
We acknowledge the German Research Society (DFG) for funding within the Collaborative Research Centre/Transregio 79 (SFB/TR 79), sub-projects B5, M2 and M5. We are grateful to Dr. C. Vater for her help during microscopy as well as the “Core Facility Cellular Imaging (CFCI)”, Faculty of Medicine of TU Dresden and A. Hild, Justus-Liebig-University Giessen, for excellent technical support.
References (53)
- et al.
Bone substitutes: an update
Injury
(2005) - et al.
Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering
Biomaterials
(2006) - et al.
Interlaboratory studies on in vitro test methods for estimating in vivo resorption of calcium phosphate ceramics
Acta Biomater.
(2015) - et al.
The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro
Bone
(1996) Strontium as therapy for osteoporosis
Curr. Opin. Pharmacol.
(2005)- et al.
In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation
Eur. J. Pharmacol.
(2002) - et al.
The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways
J. Biol. Chem.
(2009) - et al.
The effects of inorganic additives to calcium phosphate on in vitro behavior of osteoblasts and osteoclasts
Biomaterials
(2010) - et al.
A novel and easy to prepare strontium(II) modified calcium phosphate bone cement with enhanced mechanical properties
Acta Biomater.
(2013) - et al.
A novel strontium(II)-modified calcium phosphate bone cement stimulates hMSC proliferation and osteogenic differentiation in vitro
Acta Biomater.
(2013)
Bone formation induced by strontium modified calcium phosphate cement in critical-size metaphyseal fracture defects in ovariectomized rats
Biomaterials
Surface analysis by Secondary Ion Mass Spectrometry (SIMS)
Surf. Sci.
Strontium ranelate: new insights into its dual mode of action
Bone
The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation
Biochem. Pharmacol.
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis
Bone
Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro
Bone
The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin
Bone
An overview of the regulation of bone remodelling at the cellular level
Clin. Biochem.
Acid phosphatases as markers of bone metabolism
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
Unraveling the role of proteases in cancer
Clin. Chim. Acta
Bioactivity of xerogels as modulators of osteoclastogenesis mediated by connexin 43
Biomaterials
The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro
Biomaterials
Bioactive glass-based scaffolds for bone tissue engineering
Adv. Biochem. Eng. Biotechnol.
Calcium orthophosphates in medicine: from ceramics to calcium phosphate cements
Injury
Calcium orthophosphates as bioceramics: state of the art
J. Funct. Biomater.
The role of osteoclasts in bone tissue engineering
J. Tissue Eng. Regener. Med.
Cited by (73)
Enhancing bone scaffold interfacial reinforcement through in situ growth of metal–organic frameworks (MOFs) on strontium carbonate: Achieving high strength and osteoimmunomodulation
2024, Journal of Colloid and Interface ScienceImpact of Sr<sup>2+</sup> and hypoxia on 3D triple cultures of primary human osteoblasts, osteocytes and osteoclasts
2022, European Journal of Cell BiologyCitation Excerpt :On the part of osteoclasts, a reduced resorption, but no inhibition of osteoclast formation, was observed under the influence of 0.05 – 0.15 mM Sr2+ (Schumacher et al., 2016). A treatment of PBMC with more than 2 mM Sr2+ led to cytotoxic effects(Caudrillier et al., 2010; Hurtel-Lemaire et al., 2009; Schumacher et al., 2016). Lower concentrations such as 0.1 mM Sr2+ did not decrease the vitality of osteoclasts (Schumacher et al., 2016), which was confirmed in our triple culture experiments (Fig. 5).
Human osteoclast formation and resorptive function on biomineralized collagen
2022, Bioactive MaterialsCalcium phosphate-based materials regulate osteoclast-mediated osseointegration
2021, Bioactive MaterialsEnhanced osteogenic and bactericidal performance of premixed calcium phosphate cement with photocrosslinked alginate thin film
2024, Journal of Biomedical Materials Research - Part A